ZLAB
Zai Lab Reports Q3 2026 Financial Results
Zai Lab reported $108.2 million in Q3 2026 revenues. The company announced major catalysts in 2027 for its Zoci product in small cell lung cancer and ZL-1503 in immunology.
ZLAB news
Latest 3 stories · newest Nov 5, 2026
ZLAB
Zai Lab enters agreement to purchase $673M in ADSs
Zai Lab has entered into a securities purchase agreement to sell $673.2M of American Depositary Shares at $22.04 each, with gross proceeds expected to be approximately $673.2M, concurrently with a registration rights agreement.
ZLAB
Zai Lab Reports Q2 2026 Revenue of $106.3 Million
Zai Lab reported total revenues of $106.3 million in Q2 2026, achieving sequential growth driven by ZEJULA and VYVGART. The company highlighted multiple clinical pipeline advancements and confirmed momentum for potential regulatory filings next year.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same ZLAB feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/ZLAB/newsSTART FREE